For these reasons, the international guidelines recommended HCC surveillance using abdominal ultrasounds (US), with or without alpha-fetoprotein (AFP) assessment, every six months in all patients with liver cirrhosis of any aetiology and in subgroups of patients with hepatitis B virus (HBV) chronic infection without cirrhosis [20,21]. The gene discussed is AFP; the disease is hepatocellular carcinoma.